10-Q: Colgate-Palmolive Navigates Headwinds with Modest Growth

Colgate-Palmolive reports mixed Q3 2025 results with slight sales and EPS growth driven by pricing, while facing volume declines and margin pressure from higher costs.

Summary

• Net sales for the third quarter of 2025 increased by 2.0% to $5,131 million, primarily due to net selling price increases of 2.3% and positive foreign exchange of 1.2%, partially offset by volume declines of 1.5%.
• Organic sales grew by 0.4% in Q3 2025, with Oral, Personal and Home Care organic sales up 0.9% and Hills Pet Nutrition organic sales down 1.3%.
• Gross profit decreased to $3,049 million in Q3 2025 from $3,074 million in Q3 2024, with gross profit margin declining by 170 basis points to 59.4% (GAAP).
• The decline in gross profit margin was primarily due to significantly higher raw and packaging material costs (600 bps), partially offset by cost savings (290 bps), higher pricing (90 bps), and favorable mix (30 bps).
• Operating profit decreased by 1% to $1,059 million in Q3 2025, and operating profit margin decreased by 60 basis points to 20.6% (GAAP).
• Net income attributable to Colgate-Palmolive Company slightly decreased to $735 million in Q3 2025 from $737 million in Q3 2024.
• Diluted earnings per common share increased to $0.91 in Q3 2025 from $0.90 in Q3 2024.
• For the nine months ended September 30, 2025, net sales were flat at $15,152 million, with organic sales growing by 1.2%.
• Nine-month diluted EPS increased to $2.67 from $2.61 in the comparable 2024 period.
• The company acquired Care TopCo Pty Ltd (Prime100 pet food business) for approximately $301 million on April 30, 2025, expanding its Hills Pet Nutrition segment into the fresh pet food category in Australia.
• A new three-year 'Strategic Growth and Productivity Program' was approved on July 31, 2025, estimated to incur $200 million to $300 million in pre-tax charges by December 31, 2028, focusing on organizational structure, supply chain, and overhead reduction.
• A settlement agreement for $332 million was reached in the ERISA litigation matter in Q3 2025, with preliminary court approval granted in October 2025.
• The Board authorized a new $5 billion share repurchase program on March 20, 2025, replacing a previous program.
• The quarterly common stock dividend was increased to $0.52 per share from $0.50 per share, effective Q2 2025.

Sentiment

Score: 6

Explanation: The company demonstrates resilience with positive organic sales growth and EPS increases despite significant macroeconomic headwinds, volume declines, and margin pressures. Strategic acquisitions and a new productivity program indicate proactive management. However, ongoing cost inflation and competitive intensity temper a higher score.

Positives

• Net sales increased by 2.0% in Q3 2025, driven by effective pricing strategies and positive foreign exchange.
• Organic sales growth of 0.4% in Q3 2025 and 1.2% for the nine months ended September 30, 2025, indicates underlying business strength despite volume declines.
• Diluted EPS increased to $0.91 in Q3 2025 and $2.67 for the nine months, demonstrating earnings resilience.
• The acquisition of Prime100 pet food business provides strategic entry into the fast-growing fresh pet food category in Australia, enhancing the Hills Pet Nutrition segment.
• Approval of the new Strategic Growth and Productivity Program aims to drive future growth, optimize supply chain, and reduce overhead costs, signaling proactive management.
• The quarterly common stock dividend was increased to $0.52 per share, reflecting confidence in future cash flows and commitment to shareholder returns.
• Successful settlement of the ERISA litigation matter for $332 million provides clarity on a long-standing legal issue.

Negatives

• Volume declined by 1.5% in Q3 2025 and 0.5% for the nine months, indicating challenges in unit sales.
• Gross profit margin decreased by 170 basis points (GAAP) in Q3 2025, primarily due to significantly higher raw and packaging material costs (600 bps).
• Operating profit decreased by 1% in Q3 2025, and operating profit margin declined by 60 basis points (GAAP).
• Net income attributable to Colgate-Palmolive Company slightly decreased in Q3 2025.
• Advertising investment decreased by 3% in Q3 2025 and for the nine months, potentially impacting future brand building and market share.
• Market share in global toothpaste decreased by 0.5 share points year-to-date, with declines in North America, Latin America, Asia Pacific, and Africa/Eurasia.
• Organic sales in Hills Pet Nutrition decreased by 1.3% in Q3 2025, including a negative impact from lower private label pet volume (370 bps).

Risks

• Global macroeconomic, political, and market conditions are expected to remain challenging due to inflation, high interest rates, and foreign currency volatility.
• Ongoing geopolitical tensions, including the war in Ukraine, the conflict in the Middle East, and tensions between China and Taiwan, could impact supply chains, raw material availability, and consumer sentiment.
• Tariffs imposed by the United States and other countries are estimated to result in incremental gross costs of approximately $75 million in 2025.
• Continued higher raw and packaging material costs, including transactional foreign exchange impacts, may further pressure margins.
• Heightened competitive activity from local competitors, other large multinational companies, and new market entrants could impact market share and pricing power.
• Changes in trade customer policies, such as inventory destocking, fulfillment requirements, and pricing pressures, may negatively affect sales and relationships.
• The evolving retail landscape, including the growth of eCommerce and alternative channels, could create pricing pressures and impact key retailer relationships.
• The fair value of the skin health reporting unit and one indefinite-lived trademark intangible asset exceeded their carrying values by less than 20%, posing a potential risk for future impairment charges if estimates change.
• Ongoing Brazilian tax and civil proceedings, totaling approximately $112 million in tax assessments and $27 million in foreign exchange tax, present legal and financial uncertainty.
• An increasing number of talcum powder litigation cases (402 pending as of September 30, 2025, up from 308 at December 31, 2024) could lead to significant defense costs and potential liabilities, despite insurance coverage.

Future Outlook

The company anticipates global macroeconomic, political, and market conditions to remain challenging, characterized by inflation, high interest rates, foreign currency volatility, and trade tariffs. These factors are expected to continue impacting product costs and consumer demand, potentially necessitating further pricing actions. Reduced category growth is observed year-to-date and is expected to persist in the near term. The company is focused on its 2030 business strategy and the Strategic Growth and Productivity Program to drive organic sales growth, operational efficiencies, and leverage its balance sheet, aiming for consistent compounded earnings per share growth over the long term.

Management Comments

• We are a caring, innovative growth company reimagining a healthier future for all people, their pets and our planet.
• We seek to deliver consistent compounded earnings per share growth to help drive superior total shareholder return, as well as to provide Colgate-Palmolive people with an innovative and inclusive work environment.
• We are tightly focused on two product segments: Oral, Personal and Home Care; and Pet Nutrition, prioritizing efforts based on capacity to maximize core competencies and strong global equities.
• We believe increased household penetration and improved brand health are the keys to consistent organic sales growth, aiming to achieve these through science-led innovation, pursuing higher-growth adjacent categories, and expanding in faster-growing channels and markets.
• We continue to prioritize our investments in high growth and high margin segments within our Oral Care, Personal Care and Pet Nutrition businesses.
• We are building and scaling our capabilities in areas such as innovation, digital, data, analytics and artificial intelligence, enabling us to be more responsive in today's rapidly changing world.
• We expect global macroeconomic, political and market conditions to remain challenging, including as a result of inflation, high interest rates, foreign currency volatility and developments in trade relations.
• We see reduced category growth across our categories on a year-to-date basis, which we expect to continue in the near term.
• Our new 2030 business strategy and the Strategic Growth and Productivity Program, together with our strong financial condition, experience operating in challenging environments, resilient global supply chain and dedicated and diverse global team, position us well to meet the challenges ahead.

Industry Context

The consumer staples industry continues to grapple with significant macroeconomic headwinds, including persistent inflation, high interest rates, and volatile foreign currency markets, particularly in emerging economies. These factors are driving up raw material and packaging costs, forcing companies like Colgate-Palmolive to implement pricing actions which, while boosting net sales, can lead to volume declines as consumers face reduced purchasing power or shift to lower-priced alternatives, including private labels. The competitive landscape remains intense, with strong local players, large multinationals, and new entrants vying for market share through aggressive marketing and promotions. The ongoing shift towards e-commerce and alternative retail channels also presents both opportunities and challenges, creating pricing pressures and requiring significant investment in digital capabilities. Geopolitical tensions further complicate global supply chains and consumer sentiment, adding layers of uncertainty to an already complex operating environment.

Comparison to Industry Standards

• The company's gross profit margin decline of 170 basis points (GAAP) in Q3 2025, primarily due to significantly higher raw and packaging material costs (600 bps), indicates a struggle to fully offset inflationary pressures, a common challenge across the consumer goods industry.
• Volume declines of 1.5% in Q3 2025 and 0.5% for the nine months reflect a broader industry trend where pricing actions, necessary to combat inflation, often lead to reduced unit sales as consumers become more price-sensitive.
• The 0.4% organic sales growth in Q3 2025, while positive, suggests a modest performance compared to some peers who might be achieving higher organic growth through stronger innovation or market expansion in less challenged categories.
• The decrease in global toothpaste market share by 0.5 share points year-to-date, particularly in key regions like North America and Latin America, highlights intense competition from both established brands and private labels, a dynamic prevalent in mature consumer categories.
• The acquisition of Prime100 pet food business aligns with a broader industry trend of strategic M&A to enter high-growth, premium segments, such as fresh pet food, to diversify portfolios and capture new consumer demand.

Corporate Governance

Legal Proceedings

• Brazilian Tax Matters: Ongoing disputes related to the 1995 Kolynos acquisition, with tax assessments, interest, and penalties totaling approximately $112 million. The company is vigorously contesting these disallowances, believing it has strong legal grounds.
• Brazilian Civil Action: A civil action filed in 2002 seeking to annul a tax appeals decision and make the company's Brazilian subsidiary jointly and severally liable for tax due from the seller of Kolynos. The company believes it has strong legal grounds to prevail.
• Brazilian Foreign Exchange Tax: A tax assessment of approximately $27 million for foreign exchange transactions from 2000-2001. The company lost its final administrative appeal and has filed a lawsuit, believing it has strong legal grounds to contest.
• Talcum Powder Matters: 402 individual cases pending as of September 30, 2025, alleging asbestos contamination and/or causation of mesothelioma and other cancers. The company intends to vigorously contest these cases, with a significant portion of costs covered by insurance.
• ERISA Matter: A class action lawsuit regarding improper calculation of residual annuity payments. A settlement agreement for $332 million (inclusive of attorneys' fees and costs) was entered into in Q3 2025, with preliminary court approval granted in October 2025 and final approval hearing scheduled for January 2026.

Stakeholder Impact

• Shareholders: Impacted by increased diluted EPS, higher dividends, and the new $5 billion share repurchase program, indicating a commitment to shareholder returns. However, margin compression and volume declines could temper future growth expectations.
• Employees: The new Strategic Growth and Productivity Program includes initiatives to better align organizational structure and simplify operations, which may involve employee-related costs like severance and termination benefits (65% to 75% of total charges).
• Customers: Affected by net selling price increases, which contribute to sales growth but may also lead to volume declines as consumers adjust purchasing patterns due to inflation.
• Suppliers: The company's 'funding-the-growth' initiatives and supply chain optimization efforts may impact supplier relationships and pricing, while the supplier finance program offers flexibility to participating suppliers.
• Creditors: The issuance of $500 million in Senior Notes and an increase in total debt to $8,419 million impacts the company's leverage, though it maintains full compliance with debt covenants.

Next Steps

• Finalize the purchase price allocation for the Prime100 acquisition no later than the second quarter of 2026.
• Continue implementing the Strategic Growth and Productivity Program, with substantially all estimated charges ($200M-$300M) to be incurred by December 31, 2028.
• Attend the final approval hearing for the ERISA settlement, scheduled for January 2026.
• Continue to evaluate the impact of the One Big Beautiful Bill Act (OBBBA) and any additional guidance on the Inflation Reduction Act (IRA) and Pillar II Model Rules.
• Monitor and respond to ongoing federal, state, and international income tax audits and litigation matters.

Key Dates

Recommendation

Colgate-Palmolive's Q3 2025 results present a mixed picture. While diluted EPS saw a modest increase and organic sales showed growth, these were largely driven by pricing, masking underlying volume declines and significant gross margin compression due to elevated raw material costs. The company is proactively addressing challenges through strategic acquisitions (Prime100) and a new productivity program, which are positive long-term initiatives. However, the macroeconomic outlook remains challenging with persistent inflation, high interest rates, and geopolitical tensions. Ongoing legal matters, though largely settled or vigorously contested, add a layer of uncertainty. Given the current environment of cost pressures, competitive intensity, and modest organic growth, a 'hold' recommendation is appropriate. Investors should monitor the effectiveness of the new productivity program, the ability to sustain pricing without further significant volume erosion, and the impact of global economic conditions on margins and consumer demand.

Keywords

Colgate-Palmolive, CL, Consumer Staples, Personal Care, Oral Care, Home Care, Pet Nutrition, Hills Pet Nutrition, SEC Filing, 10-Q, Quarterly Results, Financial Performance, Organic Sales Growth, Gross Margin, Operating Profit, EPS, Acquisition, Prime100, Restructuring, Productivity Program, Inflation, Supply Chain, Tariffs, Litigation, Share Repurchase, Dividend